Markets & Regulations

Bellicum offloads cell therapy plant in switch to outsourced production

28-Jan-2020 By Nick Taylor

Bellicum sells cell therapy manufacturing plant to MD Anderson Cancer Center, strikes master service agreement.

Lonza poised to add 600 staff as investment peak continues into 2020

28-Jan-2020 By Nick Taylor

Lonza set to recruit 600 new staff globally at biopharma unit as spending spree continues.

Pharming plant gets EMA approval, easing Ruconest supply pressures

27-Jan-2020 By Nick Taylor

Pharming receives European approval for manufacturing plant, significantly expanding capacity.

Large pharma focusing on in-house biologic manufacture, not outsourcing

24-Jan-2020 By Ben Hargreaves

Capital expenditure is rising across the pharma industry as portfolios and pipelines shift towards biologics, but the largest companies are sticking to in-house production.

PACT Pharma raises $75M to expand cell therapy manufacturing

23-Jan-2020 By Nick Taylor

PACT Pharma reels in Series C financing round to support expansion of cell therapy manufacturing capacity.

Health plan hails success of push to boost Remicade biosimilar use

22-Jan-2020 By Nick Taylor

Health New England switched 93% of infliximab use to biosimilars after adopting a new policy.

Failure to launch? Mixed views on US biosimilar market

17-Jan-2020 By Ben Hargreaves

Differing reports on the impact of biosimilars in the US paint an unclear picture of what to expect in 2020.

Lilly acquires Dermira for $1.1bn, expands dermatology portfolio

15-Jan-2020 By Vassia Barba

Eli Lilly set to acquire dermatological drugs developer, Dermira, in an $1.1bn all-cash deal, adding commercial and late-stage drugs to its portfolio.

Astellas continues to make deals, partnering with Adaptimmune

15-Jan-2020 By Ben Hargreaves

The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.

Surging local demand drives 24% growth of Korean contract service sector

15-Jan-2020 By Nick Taylor

South Korean contract service market grows 24% as local biopharma companies step up spending.

Biocon biosimilar business valued at $3bn in funding round

14-Jan-2020 By Nick Taylor

Biocon Biologics receives True North investment that values biosimilar business at around $3bn.

FDA places Innate cancer trial on partial clinical hold over CMO issue

14-Jan-2020 By Nick Taylor

The US FDA puts Innate Pharma trial on partial clinical hold after learning of CMO problems.

Bristol-Myers offloads manufacturing plant to Catalent

13-Jan-2020 By Nick Taylor

Catalent buys Italian manufacturing and packaging plant from Bristol-Myers Squibb, adding oral solid, biologics and sterile product capacity.

Astellas acquires Xyphos and its CAR-T technology for $665m

09-Jan-2020 By Ben Hargreaves

Astellas continues its acquisition spree in the advanced therapeutics space through a deal for Xyphos and its next-generation take on CAR-T therapies.